On Sep 27, major Wall Street analysts update their ratings for $Travere Therapeutic (TVTX.US)$, with price targets ranging from $18 to $23.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and adjusts the target price from $19 to $18.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $23 to $19.
Guggenheim analyst Vamil Divan maintains with a buy rating, and adjusts the target price from $25 to $23.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and adjusts the target price from $23 to $18.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Travere Therapeutics recently announced a halt to the enrollment of their pegtibatinase phase 3 HARMONY study due to manufacturing concerns. This development is seen as a delay to the commercial portfolio, with the company anticipating a possible resumption of the trial by 2026 at the earliest. Despite the setback, the value ascribed to the program was already minimal, and the company's management has conveyed that the halt is unlikely to affect the trial's design and enrollment. Consequently, the anticipated impact on market sentiment in the near term is expected to be limited.
Travere Therapeutics announced a voluntary suspension in the enrollment for their Phase 3 HARMONY study of pegtibatinase, attributed to challenges in manufacturing scale-up. This development is seen as a setback given that pegtibatinase was anticipated to expand the company's portfolio beyond Filspari. The anticipated market introduction has now been adjusted to fiscal 2030, with the assumption that enrollment will recommence in 2026.
After Travere Therapeutics announced a voluntary pause in the Phase 3 HARMONY study for pegtibatinase in the treatment of classical homocystinuria, or HCU, it is anticipated that the timeline for broader patient enrollment and eventual commercialization will be significantly extended. It is now expected that study enrollment will recommence in 2026. Consequently, there has been a modest adjustment in the perceived probability of success for pegtibatinase, now estimated at 60%, and a corresponding two-year postponement in the projected sales timeline.
Here are the latest investment ratings and price targets for $Travere Therapeutic (TVTX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.